Chronic thromboembolic pulmonary hypertension
MONDO:0013024Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by the persistence of thromboemboli in the form of organized tissue obstructing the pulmonary arteries. The consequence is an increase in pulmonary vascular resistance (PVR) resulting in pulmonary hypertension (PH) and progressive right heart failure.
Also known as: CTEPH, Cteph, Dvt-negative, susceptibility to, pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis, susceptibility to
190 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Heart drug study halted early: limited data on right heart changes
Disease control TerminatedThis study looked at whether the drug riociguat could improve right heart size and function in people with two types of pulmonary hypertension (PAH and CTEPH). It planned to enroll 30 adults, but was terminated early, so results are limited. The goal was to use echocardiograms to…
Phase: PHASE4 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heart drug tested to fight COVID-19 complications
Disease control TerminatedThis study tested a drug called CardiolRx in 90 hospitalized COVID-19 patients who also had heart disease or risk factors like diabetes or high blood pressure. The goal was to see if the drug could lower the chance of death, needing intensive care, or having heart problems. The t…
Phase: PHASE2, PHASE3 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Xenon MRI breathes new life into lung disease detection
Diagnosis TerminatedThis study explored whether a special type of MRI using inhaled xenon gas could detect changes in the small blood vessels of the lungs in people with pulmonary hypertension. The goal was to see if this imaging method could track disease progression or response to treatment. Howev…
Phase: PHASE2 • Sponsor: Bastiaan Driehuys • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Painkiller showdown: which is safer for the heart?
Knowledge-focused TerminatedThis study looked at how two common pain relievers—celecoxib (a Coxib) and naproxen (an NSAID)—affect blood clotting in people with rheumatoid arthritis who also have heart disease or are at high risk for it. All participants took low-dose aspirin daily. The goal was to see if on…
Phase: PHASE4 • Sponsor: Platelet and Thrombosis Research, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC